The human genome is constantly threatened by multiple types of environmental and endogenous DNA-damaging agents. Unrepaired DNA damage may compromise DNA replication and transcription and elicit cytotoxic and mutagenic effects, which may eventually contribute to the development of cancer and other human diseases [1] [2] [3] [4] [5] . Most of the cells in the body exist in a slow-cycling or quiescent state, in which they exhibit very slow or no DNA replication. In these cells, it is of greater concern to understand how DNA damage interferes with the flow of genetic information during DNA transcription 1,2 . To address this question, suitable methods for measuring the effects of DNA lesions on transcription are required.
aberrant transcription induced by Dna damage may confer risk for the development of cancer and other human diseases. traditional methods for measuring lesion-induced transcriptional alterations often involve extensive colony screening and Dna sequencing procedures. Here we describe a protocol for the quantitative assessment of the effects of Dna lesions on the efficiency and fidelity of transcription in vitro and in mammalian cells. the method is also amenable to investigating the influence of specific Dna repair proteins on the biological response toward Dna damage during transcription by manipulating their gene expression. specifically, we present detailed, step-by-step procedures, including Dna template preparation, in vitro and in vivo transcription, rna purification, reverse-transcription pcr (rt-pcr) and restriction digestion of rt-pcr products. analyses of restriction fragments of interest are performed by liquid chromatography-tandem mass spectrometry (lc-Ms/Ms) and polyacrylamide gel electrophoresis (paGe). the entire procedure described in this protocol can be completed in 15-20 d. Lesion (ODN) from the nicked plasmid to generate a gapped vector. We ligate the gapped vector with a 13-mer lesion-free ODN (5′-AATTGAGTCGATG-3′) and a 12-mer lesion-carrying ODN (5′-ATGGCGXGCTAT-3′, where X = N3-CMdT, O 4 -CMdT or dT) 17 . We then purify the supercoiled plasmid DNA from the ligation mixture by agarose gel electrophoresis in the presence of ethidium bromide. We subsequently premix the lesionbearing or lesion-free control plasmid with a competitor vector (i.e., pTGFP-T7-Hha10comp; Fig. 4a ,b) and use them as DNA templates for transcription assays in vitro and in cells. We then purify the resulting transcription products and remove residual DNA contamination by DNase treatment. Next, we amplify the transcripts of interest by RT-PCR, digest the RT-PCR products with appropriate restriction enzymes and subject the restriction fragments to PAGE and LC-MS/MS analyses ( Fig. 1) .
Comparison with other methods
Compared with conventional transcriptional lesion bypass and mutagenesis assays, our CTAB method is more efficient, as it obviates the time-consuming colony screening and sequencing procedures that traditional methods require. The CTAB method enables a rapid and unambiguous identification of mutant transcripts via the incorporation of LC-MS/MS into the workflow. More importantly, the CTAB method uses the entire population of RNA progeny for lesion bypass and mutagenesis analysis, thereby enabling researchers to obtain statistically robust and quantitative conclusions regarding the ability of RNA polymerases to bypass the lesions and induce mutations during the bypass 8 .
Alternatively, a next-generation sequencing-based host cell reactivation assay was recently introduced for high-throughput measurements of lesion-induced transcriptional alterations and cellular DNA repair capacity 18 . However, this method requires an advanced computational infrastructure, and it involves comprehensive analysis and interrogation of large volumes of nextgeneration sequencing data, which is often time-consuming and is sometimes limited by the lack of technical expertise 19 .
Applications of the method
To date, our CTAB assay has been successfully used to evaluate the transcriptional blocking and miscoding potentials of 14 distinct DNA lesions, including alkylative and oxidative damage, and so on 8, [13] [14] [15] [16] . As an example, we have recently observed that N3-CMdT and O 4 -CMdT substantially inhibited DNA transcription and induced transcriptional mutagenesis in vitro and in mammalian cells by using the CTAB assay 18 (Fig. 5) . More importantly, our method can also be used to assess the influence of various repair proteins on the biological response toward DNA damage during transcription by manipulating their gene expression 8, [13] [14] [15] [16] . For example, we found that depletion of XPA, a key protein factor involved in the nucleotide excision repair pathway, exacerbated 14 the deleterious effects of N3-CMdT and O 4 -CMdT on transcription in human cells 16 (Fig. 5d-f) .
The CTAB method can be generally applied for the quantitative determination of the effects of other DNA lesions on transcription in vitro and in cells, and for the identification of the repair pathway(s) that may be involved in the removal of these DNA lesions in cells. This method can be further adapted for clinical diagnosis by testing the ability of human cells to repair DNA damage, and for drug development by screening new chemotherapeutic agents that can inhibit or enhance the DNA repair capacity in human cells.
So far, we have used the CTAB method for examining the effects of DNA lesions on transcription mediated by T7 RNA polymerase and mammalian RNA polymerase II (refs. 8,13-16) . However, this method can be used to examine how DNA lesions compromise the flow of genetic information during transcription mediated by RNA polymerases from other organisms, with the use of suitable lesion-bearing DNA templates that contain specific promoter sequences of these RNA polymerases.
Experimental design Transcription template. As a general rule, all transcription templates used for the CTAB assay should not contain any mammalian replication origins and should not replicate in mammalian cells. This allows us to exclusively determine the effects of DNA lesions on transcription in mammalian cells. The competitor vector is designed to be identical to the lesion-free control plasmid, except for the presence of three additional nucleotides between the two restriction sites used for the CTAB assay (Fig. 4a,b) . This design enables the output from a single biological experiment to be used for both transcriptional lesion bypass and mutagenesis assays, with the competitor signal (i.e., a restriction fragment arising from the transcription of the competitor vector) acting as an internal standard. The ability of RNA polymerase to bypass a lesion can be determined using the following formula: relative bypass efficiency (RBE) = (lesion signal/competitor signal)/(undamaged control signal/competitor signal). The transcriptional miscoding properties of a lesion can be determined by the relative ratio of the mutant over the sum of mutant and wild-type restriction fragments arising from the lesion-bearing genome 8 .
Gapped vector-based strategy. One challenging step of the CTAB method is the production of double-stranded DNA vectors that contain site-specifically inserted DNA lesions. The gapped vector-based strategy has been successfully established as an efficient experimental procedure to reach this goal [20] [21] [22] . As an example, we have described the construction of lesion-bearing plasmids, using pTGFP-T7-Hha10T as the parent vector with the help of the nicking endonuclease Nt.BstNBI (Fig. 3a,b) . This experimental procedure is versatile, and it can be used for any plasmid that is engineered to contain the tandem recognition sites of Nt.BstNBI or other nicking enzymes in the transcribed strand of an active gene. The incorporation of recognition sites of tandem nicking enzymes enables us to efficiently prepare gapped plasmid DNA for the site-specific incorporation of lesion-containing ODNs 20 . The length of the gap region can vary depending on the chosen DNA sequence, but the melting temperature of the corresponding gap oligomer should be below 90 °C for preventing the denaturation of the remainder of the plasmid during the partial denaturation and reannealing process 22 . For a long gap region, it is recommended to fill the gapped vector with a short lesion-bearing ODN and an undamaged ODN. For instance, we used two short oligomers (i.e., a 12-mer lesion-bearing ODN and a 13-mer undamaged ODN), but not a single 25-mer lesion-bearing ODN, for the ligation into the gapped vector (Fig. 3b) , because it is relatively easy to synthesize, purify and characterize a short lesion-bearing ODN.
The gapped vector-based strategy can be used for the incorporation of DNA lesions into the untranslated regions, as well as the protein-coding regions 21 . For instance, this strategy has been recently used to place 8-oxo-7,8-dihydroguanine in the coding region of a plasmid-borne EGFP reporter gene for investigating the mechanism of transcription inhibition induced by this lesion in cells 23 .
A complementary experimental strategy for the incorporation of a single DNA lesion into the double-stranded plasmid exploits the annealing of a synthetic lesion-bearing oligomer to a circular single-stranded DNA, extension of the lesion-bearing ODN by a DNA polymerase and ligation of the newly synthesized DNA strand 24, 25 . This approach involves tedious and time-consuming preparation of single-stranded phage DNA; however, it is a useful alternative for the construction of lesion-bearing vectors when the parent plasmids are not suitable to be engineered to contain tandem nicking enzyme sites. In addition, an experimental procedure for the construction of plasmids containing site-specific DNA interstrand cross-links has also been developed 26 .
Controls. To ligate the lesion-bearing
ODNs into the gapped vector, it is important to perform a self-ligation reaction without the inclusion of lesion-bearing ODNs. This negative control can be used to detect the potential supercoiled, lesion-free plasmid DNA, which may arise from an incomplete nicking reaction or incomplete removal of gap oligomers from the nicked plasmid.
To analyze the potential DNA contamination in the RNA template, it is necessary to include a negative control by PCR amplification of the RNA template in the absence of reverse transcription. It is also useful to include another negative control with no template, as well as a positive control with the parent plasmid as the template DNA for PCR amplification.
Restriction enzymes. The restriction digestion of RT-PCR products is a key feature of the CTAB method, which produces short ODN segments that can be readily identified and quantified by using PAGE and LC-MS/MS 8 . For example, we have used two sets of restriction enzymes, i.e., NcoI/SfaNI and MlucI/Cac8I, to digest the RT-PCR products for PAGE analysis, which enabled us to distinguish the restriction fragments with a single nucleotide difference at the lesion site 15 (Fig.  6) . In this regard, with the use of NcoI and SfaNI, we were able to resolve the 32 P-labeled d(p*CATGGCGTGCTAT, and p* designates a 32P-labeled phosphate group) (non-mutagenic product, 13-mer T) from the corresponding products carrying an A→C or A→T mutation-i.e., d(p*CATGGCGGGCTAT) (13-mer G) and d(p*CATGGCGGACTAT) (13-mer A); however, the nonmutagenic product co-migrated with the corresponding product carrying an A→G mutation opposite the lesion site, i.e., d(p*CATGGCGCGCTAT) (13-mer C) (Fig. 6b) . Alternative digestion with the use of MlucI and Cac8I enabled us to resolve the product emanating from the A→G mutation opposite the lesion site, i.e., d(p*AATTATAGCG) (10-mer G), from d(p*AATTATAGCA) (non-mutagenic product10-mer A), as well as the corresponding products carrying an A→C or A→T mutation, i.e., d(p*AATTATAGCC) (10-mer C) and d(p*AATTATAGCT) (10-mer T) (Fig. 6d) . We have also confirmed the identities of the corresponding nonradiolabeled restriction fragments of interest by LC-MS/MS analysis 15 .
Other restriction enzymes can also be used to release the restriction fragments for the CTAB assay, although appropriate modification of the parent vector by using site-directed mutagenesis 27 to accommodate these restriction sites will be needed. It is important to avoid the choice of restriction enzymes that can release multiple restriction fragments with the same or similar size as the products of interest arising from the transcription of lesion-bearing or competitor genomes. In addition, the two candidate restriction enzymes should have optimal reactivities in a single buffer.
Limitations
It is important to note that the CTAB method relies on the presence of restriction recognition sequences flanking the lesion site 8 ; thus, this approach is not suitable for the study of DNA lesions within some specific sequences that cannot be digested by restriction enzymes to produce short pieces of DNA fragments for the identification and quantification by PAGE or LC-MS/MS analysis. In addition, all existing transcriptional lesion bypass and mutagenesis assays, including the CTAB method, require the use of lesioncontaining plasmids as DNA templates for in vivo transcription. These plasmid-based model systems have been proven to be highly useful in the study of the effects of DNA lesions on the flow of genetic information during transcription 1, 2, 6, 8, 24 . However, the transcriptional blocking and miscoding potentials of DNA lesions revealed by these plasmid-based systems may differ, to some extent, from their effects on DNA transcription when they are present in chromosomal DNA in cells. Therefore, it will be of interest to develop new methods for investigating how DNA lesions located in chromosomal templates compromise the transmission of genetic information during transcription in cells in the future. MaterIals REAGENTS pTGFP-T7-Hha10T and pTGFP-T7-Hha10comp plasmids were previously constructed in our laboratory 14 •
400 mM HFIP (pH 7.0) Dilute 21.5 ml of HFIP in 500 ml of deionized water. Adjust the pH to 7.0 with triethylamine. This solution can be stored at 4 °C for up to 6 months. 2.5 mM rNTP mixture Combine 5 µl of 100 mM rATP, 5 µl of 100 mM rCTP, 5 µl of 100 mM rGTP and 5 µl of 100 mM rUTP with nuclease-free water to bring the volume to 200 µl. This solution can be stored at −20 °C for up to 6 months. 1% (wt/vol) agarose gel in 1× TAE buffer Dissolve 0.5 g of agarose in 50 ml of 1× TAE buffer by heating it in a microwave oven. Cool it to ~50 °C and add 50 µg of ethidium bromide. Pour the agarose solution into a gel tray with the well comb in place, and then allow the gel to cool at room temperature for ~30 min until it is completely solidified. This gel can be stored in a sealed condition at 4 °C for up to 2 d. 2% (wt/vol) agarose gel in 0.5× TBE buffer Dissolve 1 g of agarose in 60 ml of 0.5× TBE buffer by heating it in a microwave oven. Cool it to ~50 °C and add 50 µg of ethidium bromide. Pour the agarose into a gel tray with the well comb in place, and allow the gel to cool at room temperature for ~20 min until it is completely solidified. 
2|
To totally nick the plasmid DNA, add another 22.5 µl of Nt.BstNBI to the restriction mixture and incubate it at 55 °C for 4-6 h. ? trouBlesHootInG 3| Run 2 µl of the digestion mixture on a 1% (wt/vol) agarose gel in the presence of 1 µg/ml ethidium bromide. Run the gel in 1× TAE buffer at 80 V for ~90 min.  crItIcal step Before proceeding to the next step, confirm that the supercoiled plasmid DNA is converted to nicked plasmid DNA.
4|
Extract the restriction digestion mixture with an equal volume of a phenol:chloroform:isoamyl alcohol solution (25:24:1), and gently shake it by hand for ~5 min. Centrifuge the mixture at 15,000g for 10 min at 4 °C. ! cautIon Phenol:chloroform:isoamyl alcohol solution (25:24:1) is toxic and corrosive; wear gloves and work in a fume hood.
5|
Precipitate the aqueous layer with 2.5 volumes of 100% (vol/vol) ethanol and 0.1 volume of 3 M sodium acetate.
Incubate the mixture at −20 °C for at least 30 min, and centrifuge it at 15,000g for 60 min at 4 °C.
6|
Gently wash the DNA pellets with 500 µl of 70% (vol/vol) ethanol and centrifuge them at 15,000g for 5 min at 4 °C.  crItIcal step To avoid washing out the DNA pellets, this step should be performed extremely gently.
7|
Remove the supernatant, dry the DNA pellets and resuspend the pellets in 100 µl of sterile deionized water.
8|
In a final volume of 500 µl, mix ~5 nmol of 25-mer complementary ODN (i.e., 5′-CATCGACTCAATTATAGCACGCCAT-3′) with nicked plasmid DNA in 1× NEB buffer 3. Heat the reaction mixture at 85 °C for 5 min, and then cool it down gradually to room temperature.
9| Purify the gapped plasmid by removing the generated 25-mer duplex ODNs with a Centricon 100 spin filter (Millipore) using four changes of TE buffer according to the manufacturer's instructions. 
10|

14|
Load the ligation mixture onto a 1% (wt/vol) agarose gel in the presence of 1 µg/ml of ethidium bromide. Run it in 1× TAE buffer at 80 V for ~90 min. ! cautIon Ethidium bromide is toxic; wear gloves and avoid skin contact. 
15|
18|
Load the ligation mixture on a 1% (wt/vol) agarose gel in the presence of 1 µg/ml of ethidium bromide, and run the gel in 1× TAE buffer at 80 V for ~90 min. ! cautIon Ethidium bromide is toxic; wear gloves and avoid skin contact.
19|
Excise the band corresponding to the supercoiled plasmid DNA under a long-wavelength (365-nm) UV light source with a scalpel.  crItIcal step UV irradiation may cause damage to the plasmid DNA; use long-wavelength UV source and minimize the UV exposure time.
20|
Recover the supercoiled plasmid DNA from the gel using a Qiagen QIAquick gel extraction kit according to the manufacturer's instructions. Store the recovered plasmid DNA at −80 °C until use.  pause poInt Plasmid can be stored at −80 °C for up to 1 year.
Quality control of the lesion-bearing and lesion-free control vectors • tIMInG 1-2 d 21|
Prepare the reaction mixture given below, incubate it at 37 °C for 1 h, and then deactivate the enzyme by heating the solution at 70 °C for 20 min. 
26|
Wrap the wet gel directly in plastic wrap and expose the wrapped gel to a storage phosphor screen at 4 °C for 4-6 h.
27| Scan the phosphor screen with a Typhoon 9410 variable mode imager.
28|
Analyze the gel image with ImageQuant software according to the manufacturer's instructions.  crItIcal step Before proceeding to the next step, confirm that there is a 50-mer 32 P-labeled fragment and that there are no shorter radiolabeled fragments. 30| Prepare the reaction mixture given below, incubate it at 37 °C for 1.5 h and then deactivate the enzyme by heating the reaction solution at 70 °C for 20 min. 
34|
Wrap the wet gel directly in plastic wrap, and expose the wrapped gel to a storage phosphor screen at 4 °C for 4-6 h.
35| Scan the phosphor screen with a Typhoon 9410 variable mode imager.
36|
Quantify the bands of interest with the ImageQuant software according to the manufacturer's instructions, and normalize the relative concentration of lesion-bearing or lesion-free control plasmids to the competitor vector.  crItIcal step The lesion/competitor molar ratio can be adjusted according to the extent to which the DNA lesion blocks transcription. It is recommended that preliminary experiments be performed for optimizing this molar ratio.
In vitro and in vivo
(ii) Prepare the reaction mixture given below, incubate it at 37 °C for 1 h and then deactivate the enzyme by heating the reaction solution at 70 °C for 20 min. 
39|
Treat the purified RNA products twice with the DNA-free kit (Ambion) to eliminate DNA contamination, and subsequently remove the DNase and divalent cations from the sample according to the manufacturer's instructions.
40|
Add 16.5 µl of DNaseI-treated RNA product and 1 µl of gene-specific primer (10 pmol/µl; 5′-TCGGTGTTGCTGTGAT-3′) to a sterile RNase-free microcentrifuge tube. Heat the tube at 70 °C for 5 min, and then quickly chill it on ice.
41| Prepare the following mixture, and incubate the reaction mixture at 42 °C for 1.5 h and then at 75 °C for 15 min. 42| Prepare the PCR mixture given below. The forward and reverse primers used for this protocol are 5′-CTAGCGGATGCATCGACTC-3′ and 5′-TGCTGCGGATGATCTTGTCG-3′.  pause poInt The reaction product can be stored at −20 °C for a few days.
44| Run 3 µl of the PCR product on a 2% (wt/vol) agarose gel in 0.5× TBE buffer at 120 V for ~45 min, and expose the gel to UV light.  crItIcal step Before proceeding to the next step, confirm that the cDNA, but not RNA template, can be amplified to produce a PCR product with the expected size. (ii) Radiolabel the dephosphorylated restriction fragments as tabulated below, incubate it at 37 °C for 30 min and then deactivate the T4 PNK by heating it at 65 °C for 20 min. (Figs. 5a-c and 6b) .
? trouBlesHootInG (B) restriction digestion using MlucI and cac8I, and paGe analysis (i) Prepare the reaction mixture given below, incubate it at 37 °C for 2 h and then deactivate the enzyme by heating the reaction solution at 70 °C for 20 min. (Figs. 5a-c and 6d) .
? trouBlesHootInG (c) restriction digestion and lc-Ms/Ms analysis (i) Prepare the reaction mixture given below, incubate at 37 °C for 2 h and then deactivate the enzyme by heating the reaction solution at 70 °C for 20 min.  pause poInt The sample can be left at −20 °C for up to several months.
